Abstract
Background: Comprehensive genomic profiling (CGP) enables physicians to recommend advanced cancer treatments at the individual level by identifying patients that are likely and unlikely to benefit from targeted therapy or immunotherapy (IO). We assessed the utility of CGP-based testing for identifying biomarkers associated with approved therapies, and therapies in precision medicine basket clinical trials (CT) across a large cohort of advanced NSCLC patients in the Providence health system.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call